News Image

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Provided By GlobeNewswire

Last update: Sep 16, 2024

Houston, Texas and Tuebingen, Germany, September 16, 2024 Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Read more at globenewswire.com

IMMATICS NV

NASDAQ:IMTX (7/23/2025, 8:00:02 PM)

After market: 6.57 +0.12 (+1.86%)

6.45

+0.51 (+8.59%)



Find more stocks in the Stock Screener

Follow ChartMill for more